The critical 8p22 tumor suppressor deleted in liver cancer 1 (DLC1) is frequently inactivated by aberrant CpG methylation and/or genetic deletion and implicated in tumorigeneses of multiple tumor types. Here, we report the identification and characterization of its new isoform, DLC1 isoform 4 (DLC1-i4). This novel isoform encodes an 1125-aa (amino acid) protein with distinct N-terminus as compared with other known DLC1 isoforms. Similar to other isoforms, DLC1-i4 is expressed ubiquitously in normal tissues and immortalized normal epithelial cells, suggesting a role as a major DLC1 transcript. However, differential expression of the four DLC1 isoforms is found in tumor cell lines: Isoform 1 (longest) and 3 (short thus probably nonfunctional) share a promoter and are silenced in almost all cancer and immortalized cell lines, whereas isoform 2 and 4 utilize different promoters and are frequently downregulated. DLC1-i4 is significantly downregulated in multiple carcinoma cell lines, including 2/4 nasopharyngeal, 8/16 (50%) esophageal, 4/16 (25%) gastric, 6/9 (67%) breast, 3/4 colorectal, 4/4 cervical and 2/8(25%) lung carcinoma cell lines. The functional DLC1-i4 promoter is within a CpG island and is activated by wild-type p53. CpG methylation of the DLC1-i4 promoter is associated with its silencing in tumor cells and was detected in 38-100% of multiple primary tumors. Treatment with 5-aza-2 0 -deoxycytidine or genetic double knockout of DNMT1 and DNMT3B led to demethylation of the promoter and reactivation of its expression, indicating a predominantly epigenetic mechanism of silencing. Ectopic expression of DLC1-i4 in silenced tumor cells strongly inhibited their growth and colony formation. Thus, we identified a new isoform of DLC1 with tumor suppressive function. The differential expression of various DLC1 isoforms suggests interplay in modulating the complex activities of DLC1 during carcinogenesis.
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Introduction
Carcinogenesis involves multiple genetic/epigenetic events including the activation of oncogenes and inactivation of tumor suppressor genes (TSGs) (Fearon and Vogelstein, 1990; Knudson, 2001) . In addition to genetic mutations, a growing body of evidence has shown that TSG inactivation occurs frequently through promoter CpG methylation (Jones and Laird, 1999; Herman and Baylin, 2003) , resulting in TSG silencing and subsequent loss of function, thereby contributing to neoplastic transformation (Jones and Baylin, 2007) . Aberrant CpG methylation of TSG-associated CpG islands is a characteristic hallmark of tumor genomic DNA, and examples of methylation silenced TSGs include p16, MLH1, VHL, RAR-beta, SOCS1, PCDH10, RASAL and so on (Herman and Baylin, 2003; Jones and Baylin, 2007) .
Deleted in liver cancer 1 (DLC1) gene (also known as ARHGAP7, STARD12, HP and p122-RhoGAP) was isolated by representational difference analysis (Yuan et al., 1998 ) from a sample of human hepatocellular carcinoma (HCC), and proposed as a candidate TSG because of its frequent deletion in hepatocellular carcinoma tumors and cell lines. Located at 8p22, a site of recurrent deletion in breast, lung and prostate cancers (Yuan et al., 1998) , DLC1 encodes a protein of 1091-aa (amino acid) with extensive homology (86%) to the rat p122-RhoGAP, a GTPase-activating protein (GAP) specific for RhoA and Cdc42 that are involved in the regulation of cellular cytoskeleton organization and other functions (Homma and Emori, 1995; Yuan et al., 1998; Sekimata et al., 1999; Bernards, 2003; Wong et al., 2003; Durkin et al., 2007b) . Subsequent studies identified DLC1 as an epigenetically silenced gene with tumor suppressive and metastatic inhibitory functions in breast, liver, colon, lung, stomach and brain cancers (Kim et al., 2003; Yuan et al., 2003 Yuan et al., , 2004 Zhou et al., 2004; Pang et al., 2005) . Recently, using suppression substractive hybridization, our group identified DLC1 as an epigenetically silenced gene in nasopharyngeal (NPC), esophageal and cervical carcinomas (Seng et al., 2007) , thus, further supporting the view that DLC1 is a bona fide TSG.
DLC1 is a member of the human RhoGAP family. RhoGAP proteins share a conserved 150-200-aa GAP domain that contains the catalytic activity to convert the active GTP-bound Rho proteins to the inactive GDPbound state (Bernards, 2003; Moon and Zheng, 2003; Tcherkezian and Lamarche-Vane, 2007; Durkin et al., 2007b) . Loss of RhoGAP activity leads to aberrant activation of GTP-bound Rho proteins, which are involved in the regulation of the cell cycle, adhesion, morphogenesis, polarity and migration; and dysregulation of GTP-bound Rho proteins have been implicated in tumorigenesis (Martin, 2003; Moon and Zheng, 2003) . Members of the DLC family include DLC1, DLC2, and DLC3, and their domain structures share an N-terminal sterile a motif domain, a serine-rich domain, a RhoGAP domain and a C-terminal steroidogenic acute regulatory protein-related lipid transfer domain (Yuan et al., 1998; Ponting and Aravind, 1999; Ching et al., 2003; Durkin et al., 2007a) . Recently, Yuan et al. (2007) showed that DLC1 harbors a functional bipartite nuclear localization signal which works together with the RhoGAP and serine-rich domain to mediate DLC1 protein nuclear transfer and subsequent apoptosis in non-small-cell lung carcinoma cells . In addition, DLC1 knockdown in the background of c-myc overexpression promotes the formation of liver tumors in a murine model (Xue et al., 2008) . Taken together, these data suggest that DLC1 function both as a cytoplasmic and nuclear tumor suppressor, and highlight the importance of DLC1 in cancer development.
During our study of DLC1, we discovered a new isoform through 5 0 -rapid amplification of complementary DNA (cDNA) ends (5 0 -RACE). Here, we report the characterization of this novel isoform (designated DLC1-isoform 4 (DLC1-i4)), its mRNA expression and epigenetic alterations in multiple carcinomas. We also describe the response of the DLC1-i4 promoter to p53 and the expression of the two other DLC1 isoforms (-i1 and -i3) in human cells. Lastly, we demonstrate that DLC1-i4 and -i1 suppress tumor cell colony formation.
Results

5
0 -RNA ligase-mediated rapid amplification of cDNA ends (5 0 RLM-RACE) identifies a novel isoform of DLC1 (DLC1-i4) and expression profiles of all four isoforms in normal tissues To identify novel isoform(s) of DLC1, 5 0 -RLM-RACE was performed on NP69 and liver total RNA using antisense primers targeting the DLC1 common exons 9 and 12 (Table 1 and Figure 1a) . Two PCR bands of 205 bp and 199 bp were obtained and sequenced. Sequence analysis identified two transcriptional start sites only 6 bp apart and overlapped with a previously Exon number according to Figure 1a . BP287477) with their transcriptional start sites close to the two established by us.
We then cloned and sequenced the full-length 3,378 bp open reading frame (ORF) of DLC1-i4 from human liver RNA and identified a 1,125-aa open reading frame precisely matched with DLC1-i1 and -i2 except for a different short N-terminal region (Figure 1c and Supplementary Figure 1) . Domain analysis showed the presence of domains typical of all the DLC members (Bernards, 2003; Ching et al., 2003; Durkin et al., 2007a) (Figure 1c ). In addition, a putative mitochondrial targeting sequence was identified within the first 30 aa of DLC1-i4 using five online bioinformatics program, iPSORT, MitoProt II, Predotar, Mitopred and TargetP 1.1 server (Claros and Vincens, 1996; Bannai et al., 2002; Small et al., 2004; Guda et al., 2004a, b; Emanuelsson et al., 2007) . This sequence is coded by the unique first exon of DLC1-i4 and is absent in other isoforms ( Figure 1c and Supplementary Figure 1 ).
Genbank and Ensembl database searches querying the predicted aa sequence encoded by the new first exon found both full-length and partial mRNA transcripts coding for DLC1-i4 orthologs in mouse, rabbit, Rhesus macaque, cattle and elephant (Supplementary Figure 2) . This cDNA was thus designated DLC1-i4 in accordance with the nomenclature used by GenBank. Due to a sequence variation in the previous cDNA sequence AK025544, in silico translation of this cDNA would yield a truncated protein of 804-aa up to the end of the RhoGAP domain (Supplementary Figure 1) . With most of the available expression data on DLC1 isoform 2 only, we investigated the expression of all DLC1 isoforms including DLC1-i4 in human normal adult and fetal tissues by reverse transcription PCR (RT-PCR) using exon-specific primers to distinguish each isoform. All isoforms were detected in all normal tissues examined, with isoforms 2 and 4 showing stronger expression, and isoform 3 the weakest (Figure 1d ).
The functional DLC1-i4 promoter is upregulated by p53 and stress
We used bioinformatic screening to analyze B3 Kb upstream of the putative DLC1-i4 promoter. A CpG-island of 1087 bp spanning the promoter, exon 1 and part of intron1 was found (Takai and Jones, 2002) : GC content, 57%; observed/expected CpG ratio, 0.737; with a high concentration of 55 CpG sites in a 564-bp region (Figures 2a and 4a ). Potential transcription factor (TF)-binding sites predicted by three TF search programs (TFSEARCH, MotifSearch and MatInspector) suggest that the DLC1-i4 promoter might be regulated by TP53, E2F, STAT and heat-shock factor ( Figure 2a) .
Next, we evaluated whether the putative DLC1-i4 promoter was transcriptionally functional by cloning three fragments covering the promoter separately into a promoter-less luciferase construct and transfected celllines with/without DLC1-i4 expression (HEK293, CNE2 and HK1). All three constructs could drive transcription, with the shortest fragment (À480/ þ 140) showing the highest activity and the longest (À1840/ þ 140) showing the lowest activity (Figure 2b) , showing that the DLC1-i4 promoter is functional.
Bioinformatics analysis predicts that the DLC1-i4 promoter harbors five putative p53-binding sites ( Figure 2a ). To see whether p53 regulates this promoter, the promoter construct (pGL2-DLC1i4-PF1/R(À1840/ þ 140)) with or without a p53 expression vector was transfected into HEK293, CNE2 and the p53-null HCT116/p53KO cells, and luciferase activity was assayed. As shown in Figure 2c , p53 induced upregulation of luciferase activity ranging from 3-to 38-fold, with the highest activity observed in HCT116/p53KO cells ( Figure 2c ). Co-transfection of DLC1-i4 promoter construct with mutant p53 expression plasmids (G245C and R248W) into HCT116-p53KO, showed that only wildtype p53 could upregulate DLC1-i4 and control p21 promoter activities (10-fold and 2.5-fold, respectively) ( Figure 2d ). As the p53 mutants are defective in DNAbinding (Zhou et al., 1999; Bullock and Fersht, 2001) , this finding suggests that the ability of wild-type p53 to upregulate DLC1-i4 promoter activity is attributed to its DNA binding ability. In addition, both gene promoters showed upregulation of activity in response to increasing p53 concentration in a statistically significant (Po0.001-0.0015), dose-dependent manner up to 50 ng (Figure 2e ) before dropping off at higher p53 concentrations. Localization of the functional DLC1-i4 promoter using promoter luciferase assays. Promoter activities of three constructs containing different regions of the putative DLC1-i4 promoter relative to the promoter-less control vector using Luciferase assays are presented. Data shown are from three independent Luciferase assays ( ± s.d) in three cell lines (HEK293, CNE2 and HK1). Every one of the three different constructs of the DLC1-i4 promoter can drive the transcription of the target gene in all cell lines tested. (c) DLC1-i4 promoter is p53-responsive. The schematic diagram shows five putative p53-binding sites (BS) predicted by bioinformatics on the DLC1-i4 promoter. DLC1-i4 promoter construct were transfected into HEK293, CNE2 or HCT116/p53KO cell lines with (black bars) or without (shaded bars) TP53 expression construct, and assayed for luciferase activity after 48 h. Results of luciferase assays with respect to control pGL2 plasmid (open bars) in triplicates are shown in the histograms. The respective promoter constructs are shown on the left. Values on all histograms shown are the mean of three independent assays ( ± s.d). (d) Wild-type TP53, but not mutant TP53 is able to transactivate DLC1-i4 promoter activity. Wild-type or mutant p53 containing expression vectors were cotransfected with either DLC1-i4 promoter construct (black bars) or pGL2-p21P (open bars) into the p53-null HCT116/p53KO cell line for 48 h before luciferase activity was measured. Histograms show DLC1-i4 promoter activity upregulated by wild-type, but not mutant p53. The p21 promoter construct was used in parallel as a control for p53 transactivation. (e) TP53 upregulates DLC1-i4 promoter activity in a dose-dependent manner. Upregulation of DLC1-i4 promoter activity was observed with increasing amount of wild-type p53-expression vector. Increasing amount of the wild-type p53-expression vector (1 ng to 1 mg) was cotransfected together with either DLC1-i4 promoter construct (black bars) or pGL2-p21P (open bars) into HCT116/p53KO cell line. A two-tailed paired Student's t-test was performed to determine the statistical differences between the increasing p53 concentrations. Enh, enhancer.
We also transfected HCT116 or HCT116/p53KO cells with either the DLC1-i4 or the p21-promoter construct for 48 h before irradiation with 10 J/m 2 of UV light and assayed for luciferase activity after 2-6 h incubation. Upregulation of either DLC1-i4 or p21 promoter activities was observed (Supplementary Figure 3) , indicating that the DLC1-i4 promoter is stress-responsive.
Promoter CpG methylation silences DLC1-i4 expression in multiple carcinoma cell lines As the functional DLC1-i4 promoter contains a CpG island, we assessed whether like DLC1-i2, DLC1-i4 is also silenced in tumors. The expression of DLC1-i4, together with -i1, -i2 and -i3, were examined by semiquantitative RT-PCR in a panel of carcinoma cell lines, and we correlated DLC1-i4 expression with its promoter CpG methylation using methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS). Results showed weak or no expression of DLC1-i4 transcripts in multiple carcinoma cell lines, including 2/4 NPC, 8/ 16(50%) esophageal, 4/16(25%) gastric, 6/9(67%) breast, 3/4 colorectal, 4/4 cervical, 2/8(25%) lung carcinomas, as well as the various other cell lines tested (Figure 3 and Supplementary Figure 4) . Meanwhile, strong methylated alleles were consistently detected in cell lines without DLC1-i4 expression by MSP (Table 2, Figure 3 and Supplementary Figure 4) . In contrast, DLC1-i4 was readily detected in all normal (HMEC and HMEpC) and normal immortalized cell lines (NP69, HEK293, RHEK1, NE1 and NE3) tested, with no methylated promoter alleles detected (Table 2 and Figure 3 ). High-resolution BGS analysis performed for 55 CpG sites in the DLC1-i4 promoter (Figure 4a ) validated the MSP data (Figure 4b ). Collectively these results show that aberrant promoter CpG methylation is associated with DLC1-i4 silencing, and like DLC1-i2, is a frequent event in multiple tumors.
DLC1-i1 and -i3 share a common promoter and their expression were silenced in almost all the tumor cell lines tested (Figure 3 ). Analysis on their shared CpG poor promoter through promoter luciferase assay showed that it is a transcriptionally functional promoter (Supplementary Figure 5A and 5B). Lack of TFs to drive the expression of DLC1-i1, -i3 and -i4 was unlikely, as all promoter constructs were active in HK1, a cell line not expressing any DLC1 isoforms (Figure 3 ). Further work is required to elucidate the mechanism of the silencing of DLC1-i1 and -i3.
However, unlike DLC1-i2, DLC1-i4 is not expressed in normal peripheral blood mononuclear cells (PBMCs) with no methylated alleles detected, but is expressed in normal lymph node (Figure 1d ), indicating that mechanisms other than DNA methylation are involved in silencing of DLC1-i4 promoter in normal PBMCs (Supplementary Figure 4B) . This raised the possibility that different DLC1 isoforms might have functional Figure 4B) , correlating with methylation of the DLC1-i4 promoter.
Pharmacologic or genetic demethylation restores DLC1-i4 expression
To determine whether CpG methylation is directly implicated in the silencing of DLC1-i4, two cell lines (C666-1 and HK1) with methylated and silenced DLC1-i4 were treated with DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine (Aza). DLC1-i4 expression was restored after Aza treatment, although at different levels, with a concomitant increase in unmethylated promoter allele detected by MSP (Figure 4c ). The same phenomenon was observed when HCT116, EC109 and HK1 were treated with Aza alone, or combination with a histone deacetylase inhibitor trichostatin A (TSA) (Figure 4d ). TSA treatment alone is insufficient to induce DLC1-i4 expression, implying a critical role for DNA methylation. Moreover, for HCT116 with genetic double knockout of both DNMT1 and DNMT3B genes (HCT116-DKO cell line) (Rhee et al., 2002) , robust induction of DLC1-i4 RNA was accompanied by increased unmethylated DLC1-i4 alleles (Figure 4e ). Weak DLC1-i4 expression with some demethylated alleles were also observed in DNMT1-knockout HCT116 cells (HCT116-1KO), but knockingout DNMT3B seems to have little effect on DLC1-i4 reexpression, even though weak demethylated alleles were also detected. Subsequent high-resolution BGS methylation analysis confirmed the substantial demethylation of DLC1-i4 promoter in HCT116-DKO cells, indicating that the DLC1-i4 promoter methylation is cooperatively maintained by DNMT1 and DNMT3B (Figure 4f ).
Promoter methylation and expression of DLC1-i4
in multiple primary carcinomas DLC1-i4 methylation was next examined in multiple primary tumors, including NPC, esophageal, gastric, hepatocellular, breast and colorectal carcinoma. We first examined DLC1-i4 methylation in nine normal nasopharynx tissues and found weak methylation in only three (33%) (Figure 5a and Table 2 ), meanwhile, methylation was detected in 48/49 (98%, with two weakly methylated) endemic NPC tumors from Asian Chinese ( Figure 5a and Table 2), and in 14/30 (47%) esophageal carcinomas but less frequently in the paired non-tumor tissues ( Figure 5c and Table 2 ). In addition, DLC1-i4 methylation was detected in 9/11 (82%) primary gastric, 10/13 (77%, with two weakly methylated) breast, 14/37 (38%) HCC and 11/11 (100%) colorectal carcinomas ( Figure 5c and Table 2 ). RT-PCR and MSP analysis of primary NPC showed downregulation of DLC1-i4 expression in 5/9 specimens but weak correlation of DLC1-i4 expression with methylation of DLC1-i4 promoter (Figure 5b) . RT-PCR analysis of matched breast primary tumor and adjacent normal tissue showed DLC1-i4 downregulation in the tumor as compared with the matched normal tissue (Figure 5d ). These results indicate that DLC1-i4 methylation occurs frequently in tumors and affects DLC1-i4 expression.
DLC1-i4 suppresses tumor cell colony formation
To examine the effects of DLC1-i4 on tumor cell growth, we transfected a DLC1-i4 expression construct into HCT116, HK1 and KYSE510 cell lines, all of which have methylated and silenced endogenous DLC1-i4, and the clonogenicity of transfected cells was assessed by monolayer culture. Significant reduction in colony numbers were observed in all cell lines tested (down to B24-44% of vector control, Po0.001) (Figures 6a and b) , similar to that by TP53 (data not shown). Thus, DLC1-i4 is a functional tumor suppressor having growth inhibitory activities in tumor cells. As DLC1-i1 shares structural domains with DLC1-i4 and DLC1-i2, we tested DLC1-i1 in the same assay and showed that DLC1-i1 is also a functional tumor suppressor (Supplementary Figure 5C ).
Discussion
DLC1 is a well-defined bona fide tumor suppressor, frequently silenced in multiple tumors (Yuan et al., 1998 (Yuan et al., , 2003 Ng et al., 2000; Goodison et al., 2005; Seng et al., 2007; Xue et al., 2008) . This gene is transcribed from two different promoters, resulting in transcripts encoding three insofar known isoforms. To date, virtually all studies have focused on only one of them-the prototype DLC1-isoform 2. From our previous work on DLC1 in carcinoma (Seng et al., 2007) we identified a fourth isoform of DLC1. In this report, we provide evidence that this novel isoform 4 (DLC1-i4) codes from an alternative promoter a 1125-aa protein, which differs from DLC1-isoforms 1 and 2 at the extreme N-terminal because of the use of an alternative first exon, but nevertheless share the rest of the exons common to both isoforms and thus have the same protein domain structure. In addition, the protein sequence of DLC1-i4 was found to contain a mitochondrial targeting sequence in its first 30 aa coded for by the new first exon, a signal missing from the rest of the DLC1 isoforms. The possible mitochondria localization of DLC1-i4 however awaits further confirmation. With the variability at the N-terminal region of DLC1-i1, -i2 and -i4, it may be inferred that the conserved C-terminal region domains are critical in mediating specific proteinprotein interactions.
Similar to DLC1-i2, the DLC1-i4 promoter is hypermethylated in multiple tumor types including NPC, esophageal, gastric, breast, colorectal, cervical and HCC cell lines and primary tumors, which is associated with transcriptional silencing. Methylationmediated silencing could be reversed pharmacologically or by genetic double knockout of DNMT1 and DNMT3B. In addition, ectopic-DLC1-i4 expression in carcinoma cells shows tumor suppressive properties. In contrast, no methylation or silencing was detected in any of the immortalized normal cell line controls tested, indicating that DLC1-i4 methylation probably occurs late in carcinogenesis. The correlation between promoter methylation and gene expression in primary tumor will require further characterization in tumors other than NPC, as the presence of large proportions of nonmalignant stromal cells in NPC tumors makes clear delineation of gene expression difficult.
The use of alternative promoters and exon skipping to generate transcripts with different 5 0 -ends appear to be common among the DLC family of RhoGAPs. DLC2, a gene homologous to DLC1 at 13q12.3, yields four different transcripts to generate four protein products of differing lengths (Leung et al., 2005) . DLC3 at Xq13 was found to yield three transcripts generated by the same means (Durkin et al., 2007a) . Similar type of regulation (alternative promoters and exon variability) are also found in other TSGs, for example, TP53, APC and BRCA1 (Horii et al., 1993; Xu et al., 1995; Bourdon et al., 2005) , and is associated with the generation of proteins with different functional properties. Our data and others show that DLC1 encode four major isoforms from three alternative promoters. Interestingly, it was recently verified by 3 0 -RACE in mouse that a 6.2 Kb transcript found in the Vega database is indeed expressed and probably codes for a 127 kDa protein with a sequence nearly identical to DLC1-i4 (Sabbir et al., 2010) . The complexity and expression of different DLC1 transcripts may be a way of differential regulation to cater for different functions of each isoform.
As the tissue expression pattern of DLC1-i1 and -i3 transcripts is controversial, we addressed this question using isoform-specific primers and RT-PCR to check their expression in a panel of normal adult and fetal tissues. Our results show that all DLC1 isoforms are expressed at different levels and they have an overlapping ubiquitous expression pattern in all normal tissues tested, except that only DLC-i2 is expressed in PBMCs. Our work on the common promoter of DLC-i1 and -i3 demonstrated that it is a functional promoter, and the full-length open reading frame of DLC1-i1 does have tumor suppressor function. DLC1-i3 is unlikely to have tumor suppressor activity as it does not harbor the canonical DLC1 domains and so was not tested. The speculation that DLC1-i3 is a regulator of other DLC1 isoforms remains to be verified. Our findings are corroborated by a recently published study in which DLC1b (-DLC1-i1) and DLC1a (DLC1-i2) but not DLC1g (DLC1-i3) were shown to suppress stress fiber formation and HCC cell growth (Ko et al., 2010) . It is noteworthy that both isoforms are almost totally silenced in all tumors and immortalized normal cell lines tested, but the silencing mechanism is unclear as this promoter is not a CpG island, and could not be activated by Aza treatment (unpublished observation). Taken together, the data suggest that different DLC1 isoforms may have different functional specialization in cellular homeostasis and oncogenesis, and whether they are functionally redundant or not still needs further exploration.
p53 is an important tumor suppressor, mutated in B50% of all cancers (Efeyan and Serrano, 2007) . DLC1-i4 promoter harbors at least five putative p53 binding sites; and our data showed that it is upregulated by wild-type p53, requiring the DNA-binding ability of p53. UV treatments also moderately upregulated this promoter, similar to the p21 promoter, indicating that the DLC1-i4 promoter is p53-regulated.
In summary, we identified a new isoform of DLC1, transcribed from an alternative promoter. This novel isoform, designated DLC1-i4, was found to have tumor inhibitory properties, silenced epigenetically in multiple carcinomas and regulated by the p53 tumor suppressor. Although several important issues remain to be addressed, such as the functional overlap of each individual DLC1 isoforms, the frequent deregulation of DLC1-i4 in multiple tumors indicates that it may be an important tumor suppressor.
Materials and methods
Cell lines, tumor and normal tissue samples Tumor cell lines used in this study are described elsewhere (Ying et al., 2005b) include NPC, esophageal, gastric, breast, colorectal, cervical, lung, hepatocellular, renal, prostate, ovarian Epithelial cell lines (HMEC and HMEpC) and immortalized epithelial cell lines (NP69, RHEK1, HEK293, NE1 and NE3) were used as normal controls. Cell lines were routinely maintained in RPMI or DMEM, or Keratinocyte SFM Medium (for NP69 only) (Tsao et al., 2002; Lo et al., 2006) . Total RNA and DNA were extracted from cell pellets using TRI Reagent (Molecular Research Centre Inc., Cincinnati, OH, USA) (Tao et al., 2002) . Normal PBMCs from healthy individuals were collected as previously described (Cheung et al., 1993) . Human normal adult and fetal tissue RNA samples were purchased commercially (Ying et al., 2005a; Seng et al., 2007) . RNA from matched human breast primary tumor and normal tissue pair was purchased from Biochain (Hayward, CA, USA). DNA extracted from primary tumors are described elsewhere (Tao et al., 1998 (Tao et al., , 1999 Qiu et al., 2004; Ying et al., 2005a, b; Seng et al., 2007; Cui et al., 2008) .
5
0 RLM-RACE 5 0 -RLM-RACE was carried out with RNA from NP69 cell line and liver RNA (BD Clontech, Palo Alto, CA, USA), using the FirstChoice RLM-RACE kit (Ambion Inc., Austin, TX, USA) according to the manufacturer's protocol. Reverse transcription was carried out with random hexamers and nested PCR used to amplify the 5 0 end of DLC1 transcripts using kit provided sense primers and antisense primers specific to both DLC1-i1 and -i2 (Primer sequences available in Table 1 ). Nested PCR amplification was carried out in a 25 ml volume consisting of 1 ml of cDNA, 0.6 U of AmpliTaq Gold (PE Biosystems, Foster City, CA, USA), 0.6 mM of each primer, and 2 mM MgCl 2 . The amplification cycle involve an initial 'hot start' at 95 1C for 10 min, followed by 35 cycles of amplifications (94 1C, 30 s; 55 1C, 30 s; 72 1C, 2 min) with a final extension step of 72 1C for 10 min. Nested PCR reaction was diluted 10 Â with sterile water and 1 ml of the diluted reaction was used for subsequent nested PCR with the same conditions. PCR products were analyzed on 1.8% agarose gels. Two bands of 205 bp and 199 bp from Liver and NP69, respectively, were excised, purified and sequenced with the ABI PRISM BigDye v1.1 Kit (PE Biosystems) with the inner primer E10R.
Bioinformatics analysis
Sequences obtained were analyzed using BLASTN (Altschul et al., 1990) program (www.ncbi.nlm.nih.gov/blast). Gene structure and orthologs were obtained from GenBank (www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD ¼ search&DB ¼ gene) and Ensembl databases (http://www.ensembl.org) (Maglott et al., 2007; Flicek et al., 2010) . Alignment of aa sequences and phylogenetic tree generation were carried out using the ClustalW2 program (http://www.ebi.ac.uk/ Tools/clustalw2/index.html) (Larkin et al., 2007) and shaded using BioEdit 7.0.1 (www.mbio.ncsu.edu/BioEdit/bioedit.html) (Hall, 1999) . Potential TF-binding sites on DLC1-i4 promoter were predicted using TFSEARCH (www.cbrc.jp/research/db/ TFSEARCH.html) (Yutaka Akiyama, 1995; Heinemeyer et al., 1998) , MotifSearch (www.motif.genome.jp/) (Heinemeyer et al., 1999) and MatInspector (www.genomatix.de) (Cartharius et al., 2005) . CpG island was predicted with CpG Island Searcher (www.uscnorris.com/cpgislands2/cpg.aspx) Jones, 2002, 2003) using default settings. N-terminal signal peptide analysis were done using iPSORT (http://hc.ims. u-tokyo.ac.jp/iPSORT/) (Bannai et al., 2002) , MitoProt II (http://ihg2.helmholtz-muenchen.de/ihg/mitoprot.html) (Claros and Vincens, 1996) , Predotar (http://urgi.versailles.inra.fr/ predotar/predotar.html) (Small et al., 2004) , Mitopred (http:// bioapps.rit.albany.edu/MITOPRED/) (Guda et al., 2004a, b) and TargetP 1.1 (http://www.cbs.dtu.dk/services/TargetP/) (Emanuelsson et al., 2007) .
Semi-quantitative RT-PCR
RT-PCR was done as previously described (Tao et al., 1998 (Tao et al., , 2002 , with primers in Table 1 , together with house-keeping gene GAPDH as a control. RT-PCR was performed for 35 cycles for all genes except GAPDH (25 cycles), using the GeneAmp RNA PCR system (Applied Biosystems).
Gene reporter assays
From normal placenta DNA (Sigma-Aldrich Corporation, St Louis, MO, USA), three regions of the putative DLC1-i4 and -i1 promoter were PCR amplified using a high-fidelity DNA polymerase, Phusion (Finnzymes, Espoo, Finland) and ligated to the promoter-less pGL2-Enhancer vector (Promega, Madison, WI, USA) to create pGL2-DLC1i4-PF1/R(À1840/ þ 140), pGL2-DLC1i4-PF2/R(À960/ þ 140), pGL2-DLC1i4-PF3/R(À480/ þ 140); pGL2-DLC1i1-F1/R(À1272/ þ 286), pGL2-DLC1i1-F2/R(À656/ þ 286) and pGL2-DLC1i1-F3/R(À376/ þ 286). The p21 promoter plasmid (pGL2-p21P) was a kind gift from Drs Satya Narayan and Bert Vogelstein (University of Florida, Gainesville, FL, USA; Johns Hopkins, Baltimore, MD, USA). Plasmids used for transfection were prepared and purified using the Endofree Plasmid Maxi Kit from Qiagen (Qiagen GmbH, Germany). Promoter activities were tested by co-transfection of cell lines (HEK293, CNE2 and HK1) in 12-well plates with 2 mg of promoter construct and 100 ng of Renilla Luciferase plasmid pRL-SV40 as an internal control using Fugene 6 (Roche Diagnostics, Mannheim, Germany). Transfected cells were grown for 48 h before luciferase assay using the Dual Luciferase Reporter Assay System (Promega). Three independent assays were conducted and the mean ± s.d. values were calculated.
To assess the effect of p53 on DLC1-i4 promoter activity, concentrations of the p53 expression vector ranging from 1 to 500 ng (pcDNA3.1( þ )TP53) or two mutant p53 expression constructs (G245C and R248W) (gifts from Bert Vogelstein) were cotransfected with 2 mg of pGL2-DLC1i4-PF1/R(À1840/ þ 140) and 100 ng pRL-SV40 into respective cells lines. For comparative purposes, the p21 promoter construct pGL2-p21P was used as a positive control for p53-dependent transcriptional activation. For UV treatment, cells after transfection are allowed to grow for 48 h and the growth medium removed before irradiation with 10 J/m 2 UV in a Stratalinker UV Crosslinker 1800 (Stratagene, La Jolla, CA, USA). After UV irradiation, growth media were replaced and incubated for a further 2-6 h before luciferase assay.
Construction of expression plasmids
The full-length cDNA of DLC1-i4 and -i1 with a Hemagglutinin tag at its N-terminus and its ATG 'start' codon within a Kozak consensus sequence (Kozak, 1986 (Kozak, , 1987 , and the common 'stop' codon present in exon 21 (Figure 1a ) was PCR cloned from human liver-tissue RNA (BD Clontech) using a high-fidelity DNA polymerase, Phusion . The cDNA was then restriction enzyme digested, cloned into the expression vector pcDNA3.1( þ ) (Invitrogen, Carlsbad, CA, USA) and sequenced. pcDNA3.1( þ )TP53 was constructed by subcloning the full-length wild-type TP53 from plasmid pC53-SN (gift from Dr Bert Vogelstein) into pcDNA3.1( þ ). The two mutant p53 expression constructs (G245C & R248W) were also gifts from Dr Bert Vogelstein.
Bisulfite treatment and promoter methylation analysis Bisulfite modification of DNA and the subsequent MSP and BGS analyses were previously described (Tao et al., 1999 (Tao et al., , 2002 . MSP and BGS primer sets are listed in Table 1 . All primer sets were previously tested for not amplifying any unbisulfited DNA. For BGS, the PCR products were TA-cloned into the pCR2.1-TOPO vector (Invitrogen) and 5-12 colonies were randomly chosen and sequenced. All PCR reactions were carried out using the AmpliTaq-Gold DNA polymerase (Applied Biosystems).
Aza and TSA treatment
Freshly seeded cells (C666-1 and HK1) at a concentration of 1 Â 10 5 cells per ml in T-75 flasks were grown overnight with fresh medium containing Aza (Sigma-Aldrich Corporation) at a final concentration of 50 mM (Qiu et al., 2004; Ying et al., 2005b) . Cells were treated continuously for 72 or 144 h, with the Aza-containing medium changed every 24 h before being harvested for DNA and RNA extraction. For TSA treatment, cells (HCT116, EC109 and HK1) were treated as above for 72 h using 10 mM of Aza and subsequently for another 24 h with 100 ng/ml TSA.
Colony formation assays HCT116, HK1 and EC109 cells (3 Â 10 5 cells per ml) were plated in a 12-well plate and allowed to grow for 24 h before being transfected with 2 mg of expression plasmids or empty vector using Fugene 6 (Roche Diagnostics) according to the manufacturer's protocol. At 48 h post-transfection, transfected cells were trypsinized and diluted into 6-well plates with G-418 (500 mg/ml) selection for 2-3 weeks. Surviving colonies (with 450 cells per colony) were counted and analyzed after staining with Gentian Violet. The experiment was repeated thrice independently.
